Live Stock Coverage: Will Nabriva Therapeutics AG – ADR Short Squeeze Soon?

Live Stock Coverage: Will Nabriva Therapeutics AG   ADR Short Squeeze Soon?

The stock of Nabriva Therapeutics AG – ADR (NASDAQ:NBRV) reached all time low today, Nov, 3 and still has $4.43 target or 11.00% below today’s $4.98 share price. This indicates more downside for the $105.94M company. This technical setup was reported by Barchart.com. If the $4.43 PT is reached, the company will be worth $11.65 million less.
Trading stocks at an all time low is not easy. Stock at an all time low usually experience even more downside due to very negative fundament. Even thought the pullback rate is high, shorting is not an easy job because the risk of being wrong is big and the risk-reward ratio is always worse than if trading lon only. The stock decreased 9.29% or $0.51 on November 3, hitting $4.98. About 87,545 shares traded hands or 429.48% up from the average. Nabriva Therapeutics AG – ADR (NASDAQ:NBRV) has declined 38.38% since April 1, 2016 and is downtrending. It has underperformed by 39.60% the S&P500.

Nabriva Therapeutics AG – ADR (NASDAQ:NBRV) Ratings Coverage

Out of 5 analysts covering Nabriva Therapeutics (NASDAQ:NBRV), 5 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Nabriva Therapeutics has been the topic of 7 analyst reports since October 12, 2015 according to StockzIntelligence Inc. On Monday, October 12 the stock rating was initiated by Needham with “Buy”. The firm has “Outperform” rating by RBC Capital Markets given on Thursday, November 12. The rating was reinitiated by Leerink Swann with “Outperform” on Thursday, October 27. The stock of Nabriva Therapeutics AG – ADR (NASDAQ:NBRV) has “Outperform” rating given on Tuesday, October 13 by Wedbush. As per Tuesday, October 13, the company rating was initiated by Leerink Swann. The rating was initiated by RBC Capital Markets with “Outperform” on Tuesday, October 13. Gabelli initiated Nabriva Therapeutics AG – ADR (NASDAQ:NBRV) rating on Wednesday, January 27. Gabelli has “Buy” rating and $14 price target.

According to Zacks Investment Research, “Nabriva Therapeutics AG is a biopharmaceutical company. The Company is involved in the research and development of novel anti-infective agents to treat serious infections, which focus on the pleuromutilin class of antibiotics. Its product candidate consists of BC-3781, developed for the treatment of serious skin infections and bacterial pneumonia caused by MRSA and other drug resistant bacteria; BC-7013, a topical pleuromutilin antibiotic which are in different clinical trial. Nabriva Therapeutics AG is based in Vienna, Austria.”

More recent Nabriva Therapeutics AG – ADR (NASDAQ:NBRV) news were published by: Benzinga.com which released: “Leerink: Time To Buy Nabriva Therapeutics’ ‘Unique Differentiation'” on October 13, 2015. Also Benzinga.com published the news titled: “Benzinga’s Top Initiations” on October 27, 2016. Investorplace.com‘s news article titled: “11 Pharmaceuticals Stocks to Sell Now” with publication date: October 21, 2016 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags:

Related posts

Leave a Comment